Hmdb loader
Record Information
Version5.0
StatusExpected but not Quantified
Creation Date2006-05-22 15:12:16 UTC
Update Date2021-09-14 15:48:27 UTC
HMDB IDHMDB0002873
Secondary Accession Numbers
  • HMDB02873
Metabolite Identification
Common NameDeacetyldiltiazem
DescriptionDeacetyldiltiazem is a metabolite product of the drug Diltiazem (a coronary vasodilator), and is present in the plasma of individuals taking that medication. (PMID 2328299 ). The action mechanisms involved in the effect of Deacetyldiltiazem on blood rheological (erythrocyte deformation) properties appeared to be similar to Diltiazem, but different from other metabolites of this drug. (PMID 3411434 ).
Structure
Data?1582752257
Synonyms
ValueSource
DiltiazemHMDB
Deacetyldiltiazem, (cis)-isomerMeSH, HMDB
DesacetyldiltiazemMeSH, HMDB
Deacetyldiltiazem hydrochloride, (cis-(+-))-isomerMeSH, HMDB
Deacetyldiltiazem hydrochloride, (cis)-isomerMeSH, HMDB
Deacetyldiltiazem hydrochloride, (trans)-isomerMeSH, HMDB
DeacetyldiltiazemMeSH
Chemical FormulaC20H24N2O3S
Average Molecular Weight372.481
Monoisotopic Molecular Weight372.150763334
IUPAC Name(2S,3S)-5-[2-(dimethylamino)ethyl]-3-hydroxy-2-(4-methoxyphenyl)-2,3,4,5-tetrahydro-1,5-benzothiazepin-4-one
Traditional Namedesacetyldiltiazem
CAS Registry Number42399-40-6
SMILES
COC1=CC=C(C=C1)[C@@H]1SC2=CC=CC=C2N(CCN(C)C)C(=O)[C@@H]1O
InChI Identifier
InChI=1S/C20H24N2O3S/c1-21(2)12-13-22-16-6-4-5-7-17(16)26-19(18(23)20(22)24)14-8-10-15(25-3)11-9-14/h4-11,18-19,23H,12-13H2,1-3H3/t18-,19+/m1/s1
InChI KeyNZHUXMZTSSZXSB-MOPGFXCFSA-N
Chemical Taxonomy
Description Belongs to the class of organic compounds known as benzothiazepines. These are organic compounds containing a benzene fused to a thiazepine ring (a seven-membered ring with a nitrogen atom and a sulfur atom replacing two carbon atoms).
KingdomOrganic compounds
Super ClassOrganoheterocyclic compounds
ClassBenzothiazepines
Sub ClassNot Available
Direct ParentBenzothiazepines
Alternative Parents
Substituents
  • Benzothiazepine
  • Phenol ether
  • Methoxybenzene
  • Anisole
  • Aryl thioether
  • Phenoxy compound
  • Alkyl aryl ether
  • Alkylarylthioether
  • Benzenoid
  • Monocyclic benzene moiety
  • Tertiary carboxylic acid amide
  • Carboxamide group
  • Secondary alcohol
  • Tertiary aliphatic amine
  • Tertiary amine
  • Amino acid or derivatives
  • Lactam
  • Azacycle
  • Carboxylic acid derivative
  • Ether
  • Thioether
  • Organic nitrogen compound
  • Alcohol
  • Carbonyl group
  • Hydrocarbon derivative
  • Organic oxide
  • Organopnictogen compound
  • Amine
  • Organic oxygen compound
  • Organonitrogen compound
  • Organooxygen compound
  • Aromatic heteropolycyclic compound
Molecular FrameworkAromatic heteropolycyclic compounds
External DescriptorsNot Available
Ontology
Physiological effectNot Available
Disposition
ProcessNot Available
RoleNot Available
Physical Properties
StateSolid
Experimental Molecular Properties
PropertyValueReference
Melting PointNot AvailableNot Available
Boiling PointNot AvailableNot Available
Water SolubilityNot AvailableNot Available
LogPNot AvailableNot Available
Experimental Chromatographic PropertiesNot Available
Predicted Molecular Properties
PropertyValueSource
Water Solubility0.12 g/LALOGPS
logP2.31ALOGPS
logP2.29ChemAxon
logS-3.5ALOGPS
pKa (Strongest Acidic)12.33ChemAxon
pKa (Strongest Basic)8.18ChemAxon
Physiological Charge1ChemAxon
Hydrogen Acceptor Count4ChemAxon
Hydrogen Donor Count1ChemAxon
Polar Surface Area53.01 ŲChemAxon
Rotatable Bond Count5ChemAxon
Refractivity105.21 m³·mol⁻¹ChemAxon
Polarizability39.29 ųChemAxon
Number of Rings3ChemAxon
BioavailabilityYesChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleNoChemAxon
MDDR-like RuleNoChemAxon
Predicted Chromatographic Properties

Predicted Collision Cross Sections

PredictorAdduct TypeCCS Value (Å2)Reference
DarkChem[M+H]+190.39131661259
DarkChem[M-H]-192.05831661259
DeepCCS[M+H]+182.10830932474
DeepCCS[M-H]-179.74730932474
DeepCCS[M-2H]-213.18330932474
DeepCCS[M+Na]+188.4130932474
AllCCS[M+H]+190.032859911
AllCCS[M+H-H2O]+187.332859911
AllCCS[M+NH4]+192.532859911
AllCCS[M+Na]+193.232859911
AllCCS[M-H]-190.232859911
AllCCS[M+Na-2H]-190.432859911
AllCCS[M+HCOO]-190.732859911

Predicted Kovats Retention Indices

Underivatized

MetaboliteSMILESKovats RI ValueColumn TypeReference
DeacetyldiltiazemCOC1=CC=C(C=C1)[C@@H]1SC2=CC=CC=C2N(CCN(C)C)C(=O)[C@@H]1O4358.0Standard polar33892256
DeacetyldiltiazemCOC1=CC=C(C=C1)[C@@H]1SC2=CC=CC=C2N(CCN(C)C)C(=O)[C@@H]1O2873.3Standard non polar33892256
DeacetyldiltiazemCOC1=CC=C(C=C1)[C@@H]1SC2=CC=CC=C2N(CCN(C)C)C(=O)[C@@H]1O3040.1Semi standard non polar33892256

Derivatized

Derivative Name / StructureSMILESKovats RI ValueColumn TypeReference
Deacetyldiltiazem,1TMS,isomer #1COC1=CC=C([C@@H]2SC3=CC=CC=C3N(CCN(C)C)C(=O)[C@@H]2O[Si](C)(C)C)C=C12953.6Semi standard non polar33892256
Deacetyldiltiazem,1TBDMS,isomer #1COC1=CC=C([C@@H]2SC3=CC=CC=C3N(CCN(C)C)C(=O)[C@@H]2O[Si](C)(C)C(C)(C)C)C=C13141.0Semi standard non polar33892256
Spectra

GC-MS Spectra

Spectrum TypeDescriptionSplash KeyDeposition DateSourceView
Predicted GC-MSPredicted GC-MS Spectrum - Deacetyldiltiazem GC-MS (Non-derivatized) - 70eV, Positivesplash10-0a4l-6968000000-31d69e76cb441c8eb4682017-09-01Wishart LabView Spectrum
Predicted GC-MSPredicted GC-MS Spectrum - Deacetyldiltiazem GC-MS (1 TMS) - 70eV, Positivesplash10-0ab9-9222300000-7e8a04693a2f019c8e3e2017-10-06Wishart LabView Spectrum
Predicted GC-MSPredicted GC-MS Spectrum - Deacetyldiltiazem GC-MS (Non-derivatized) - 70eV, PositiveNot Available2021-10-12Wishart LabView Spectrum

MS/MS Spectra

Spectrum TypeDescriptionSplash KeyDeposition DateSourceView
Experimental LC-MS/MSLC-MS/MS Spectrum - Deacetyldiltiazem Quattro_QQQ 10V, Positive-QTOF (Annotated)splash10-00di-0309000000-4f78253225444d766ea12012-07-25HMDB team, MONAView Spectrum
Experimental LC-MS/MSLC-MS/MS Spectrum - Deacetyldiltiazem Quattro_QQQ 25V, Positive-QTOF (Annotated)splash10-004i-1900000000-1318fea4679c168e8d972012-07-25HMDB team, MONAView Spectrum
Experimental LC-MS/MSLC-MS/MS Spectrum - Deacetyldiltiazem Quattro_QQQ 40V, Positive-QTOF (Annotated)splash10-056s-0900000000-497dbcafd358c52264272012-07-25HMDB team, MONAView Spectrum
Experimental LC-MS/MSLC-MS/MS Spectrum - Deacetyldiltiazem 50V, Positive-QTOFsplash10-0ufr-0900000000-007ed6981e6a7674cea32021-09-20HMDB team, MONAView Spectrum
Experimental LC-MS/MSLC-MS/MS Spectrum - Deacetyldiltiazem 20V, Positive-QTOFsplash10-00b9-0907000000-69fc05ea7be6f47f006b2021-09-20HMDB team, MONAView Spectrum
Experimental LC-MS/MSLC-MS/MS Spectrum - Deacetyldiltiazem 10V, Positive-QTOFsplash10-00di-0009000000-74bf9165b0dca218f5172021-09-20HMDB team, MONAView Spectrum
Experimental LC-MS/MSLC-MS/MS Spectrum - Deacetyldiltiazem 30V, Positive-QTOFsplash10-004i-0900000000-13b286bd59bfa08ca3f62021-09-20HMDB team, MONAView Spectrum
Experimental LC-MS/MSLC-MS/MS Spectrum - Deacetyldiltiazem 40V, Positive-QTOFsplash10-0fb9-0900000000-b831c8e8da4a17767b722021-09-20HMDB team, MONAView Spectrum
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - Deacetyldiltiazem 10V, Positive-QTOFsplash10-00di-2109000000-4f4d8b04f6fb38782b6c2017-09-01Wishart LabView Spectrum
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - Deacetyldiltiazem 20V, Positive-QTOFsplash10-00di-5933000000-444752d9e318a3bdc1f12017-09-01Wishart LabView Spectrum
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - Deacetyldiltiazem 40V, Positive-QTOFsplash10-05fr-7900000000-727d8d2bd166506d75c52017-09-01Wishart LabView Spectrum
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - Deacetyldiltiazem 10V, Negative-QTOFsplash10-00di-0009000000-f7c98d8fc7f115cdcf722017-09-01Wishart LabView Spectrum
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - Deacetyldiltiazem 20V, Negative-QTOFsplash10-0ht9-0439000000-399a4eb4aff7fe5b62f92017-09-01Wishart LabView Spectrum
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - Deacetyldiltiazem 40V, Negative-QTOFsplash10-0zfr-1930000000-637a90a35ba5c3d966642017-09-01Wishart LabView Spectrum
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - Deacetyldiltiazem 10V, Negative-QTOFsplash10-00di-0009000000-7527d5f0c7e68d3bff362021-09-23Wishart LabView Spectrum
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - Deacetyldiltiazem 20V, Negative-QTOFsplash10-0uk9-0198000000-ea4b553a352be30901352021-09-23Wishart LabView Spectrum
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - Deacetyldiltiazem 40V, Negative-QTOFsplash10-0536-0691000000-10d11ae35e2a14440fab2021-09-23Wishart LabView Spectrum
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - Deacetyldiltiazem 10V, Positive-QTOFsplash10-00di-0009000000-5a8213501fca1b97c1f62021-09-24Wishart LabView Spectrum
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - Deacetyldiltiazem 20V, Positive-QTOFsplash10-00di-7209000000-9bcca83a8288485186362021-09-24Wishart LabView Spectrum
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - Deacetyldiltiazem 40V, Positive-QTOFsplash10-00di-5931000000-c443a5ed8d50f8d8e7e52021-09-24Wishart LabView Spectrum

NMR Spectra

Spectrum TypeDescriptionDeposition DateSourceView
Experimental 1D NMR1H NMR Spectrum (1D, 600 MHz, H2O, experimental)2012-12-05Wishart LabView Spectrum
Experimental 2D NMR[1H, 13C]-HSQC NMR Spectrum (2D, 600 MHz, H2O, experimental)2012-12-05Wishart LabView Spectrum
Biological Properties
Cellular Locations
  • Membrane (predicted from logP)
Biospecimen LocationsNot Available
Tissue Locations
  • Kidney
  • Liver
  • Platelet
Pathways
Normal Concentrations
Not Available
Abnormal Concentrations
Not Available
Associated Disorders and Diseases
Disease ReferencesNone
Associated OMIM IDsNone
DrugBank IDNot Available
Phenol Explorer Compound IDNot Available
FooDB IDFDB023076
KNApSAcK IDNot Available
Chemspider ID82743
KEGG Compound IDNot Available
BioCyc IDNot Available
BiGG IDNot Available
Wikipedia LinkNot Available
METLIN ID2271
PubChem Compound91638
PDB IDNot Available
ChEBI IDNot Available
Food Biomarker OntologyNot Available
VMH IDNot Available
MarkerDB IDNot Available
Good Scents IDNot Available
References
Synthesis ReferenceNot Available
Material Safety Data Sheet (MSDS)Download (PDF)
General References
  1. Mahmood I, Sahajwalla C: Clinical pharmacokinetics and pharmacodynamics of buspirone, an anxiolytic drug. Clin Pharmacokinet. 1999 Apr;36(4):277-87. [PubMed:10320950 ]
  2. Vivian EM, Goebig ML: Slowing the progression of renal disease in diabetic patients. Ann Pharmacother. 2001 Apr;35(4):452-63. [PubMed:11302410 ]
  3. Gashti CN, Bakris GL: The role of calcium antagonists in chronic kidney disease. Curr Opin Nephrol Hypertens. 2004 Mar;13(2):155-61. [PubMed:15202609 ]
  4. Shamim W, Bakhai A, Yousufuddin M, Coats AJ: Increased urinary cortisol and androgen metabolites in a young female with hypertension: partial glucocorticoid resistance syndrome. Cardiology. 2000;93(1-2):131-2. [PubMed:10894920 ]
  5. Mousa O, Brater DC, Sunblad KJ, Hall SD: The interaction of diltiazem with simvastatin. Clin Pharmacol Ther. 2000 Mar;67(3):267-74. [PubMed:10741630 ]
  6. Abadin JA, Duran JA, Perez de Leon JA: Probable diltiazem-induced acute interstitial nephritis. Ann Pharmacother. 1998 Jun;32(6):656-8. [PubMed:9640485 ]
  7. Mies S, Massarollo PC, Figueira ER, Leitao RM, Raia S: Lower incidence of liver graft rejection in patients on diltiazem plus cyclosporine therapy. Transplant Proc. 1998 Jun;30(4):1437-8. [PubMed:9636582 ]
  8. Kawano Y, Makino Y, Okuda N, Takishita S, Omae T: Effects of diltiazem retard on ambulatory blood pressure and heart rate variability in patients with essential hypertension. Blood Press Monit. 2000 Jun;5(3):181-5. [PubMed:10915232 ]
  9. Zhao XJ, Jones DR, Wang YH, Grimm SW, Hall SD: Reversible and irreversible inhibition of CYP3A enzymes by tamoxifen and metabolites. Xenobiotica. 2002 Oct;32(10):863-78. [PubMed:12419016 ]
  10. Zucker ML, Budd SE, Dollar LE, Chernoff SB, Altman R: Effect of diltiazem and low-dose aspirin on platelet aggregation and ATP release induced by paired agonists. Thromb Haemost. 1993 Aug 2;70(2):332-5. [PubMed:8236144 ]
  11. Zhang XL, Xu B, Feng Y: Effects of diltiazem on down-regulation of lymphocyte beta-adrenoceptors in patients with chronic congestive heart failure. Acta Pharmacol Sin. 2000 Oct;21(10):927-30. [PubMed:11501046 ]
  12. Fukuoka Y, Tachibana T, Yasui A: Anaphylatoxin C3a induces rapid protein phosphorylation in guinea pig platelets. Immunopharmacology. 1994 Sep-Oct;28(2):95-104. [PubMed:8002292 ]
  13. Dimmitt DC, Bhargava VO, Arumugham T, Eller M, Weir SJ: Relative bioavailability of Cardizem CD and Tiazac controlled-release diltiazem dosage forms after single and multiple dosing in healthy volunteers. Am J Ther. 1998 May;5(3):173-9. [PubMed:10099056 ]
  14. Sperschneider H, Wagner C, Korn A, Christians U: [Effect of diltiazem on concentration of cyclosporin metabolites in Sandimmune and Neoral treated kidney transplant patients]. Med Klin (Munich). 1997 Oct 15;92(10):589-96. [PubMed:9446006 ]
  15. Morimoto Y, Kemmotsu O, Gando S, Shibano T, Shikama H: The effect of calcium channel blockers on cerebral oxygenation during tracheal extubation. Anesth Analg. 2000 Aug;91(2):347-52. [PubMed:10910846 ]
  16. Mayhew BS, Jones DR, Hall SD: An in vitro model for predicting in vivo inhibition of cytochrome P450 3A4 by metabolic intermediate complex formation. Drug Metab Dispos. 2000 Sep;28(9):1031-7. [PubMed:10950845 ]
  17. Odawara A, Kikkawa K, Katoh M, Toryu H, Shimazaki T, Sasaki Y: Inhibitory effects of TA-993, a new 1,5-benzothiazepine derivative, on platelet aggregation. Circ Res. 1996 Apr;78(4):643-9. [PubMed:8635222 ]
  18. Jones TE, Morris RG: Pharmacokinetic interaction between tacrolimus and diltiazem: dose-response relationship in kidney and liver transplant recipients. Clin Pharmacokinet. 2002;41(5):381-8. [PubMed:12036394 ]
  19. Tateishi T, Ohashi K, Fujimura A, Ebihara A: The influence of diltiazem versus cimetidine on propranolol metabolism. J Clin Pharmacol. 1992 Dec;32(12):1099-104. [PubMed:1487547 ]
  20. Roth M, Eickelberg O, Kohler E, Erne P, Block LH: Ca2+ channel blockers modulate metabolism of collagens within the extracellular matrix. Proc Natl Acad Sci U S A. 1996 May 28;93(11):5478-82. [PubMed:8643600 ]
  21. Du Souich P, Lery N, Lery L, Varin F, Boucher S, Vezina M, Pilon D, Spenard J, Caille G: Influence of food on the bioavailability of diltiazem and two of its metabolites following the administration of conventional tablets and slow-release capsules. Biopharm Drug Dispos. 1990 Mar;11(2):137-47. [PubMed:2328299 ]
  22. Shibata N, Morita K, Ono T, Nishikawa S, Kinoshita M, Kawakita S, Takada K, Muranishi S, Shimakawa H: Effects of diltiazem on rheological properties of human blood. J Pharmacobiodyn. 1988 Mar;11(3):175-80. [PubMed:3411434 ]